Neurocrine Biosciences, Inc. Stock Berne S.E.
Equities
NB3
US64125C1099
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
111.6 CHF | -.--% |
|
-.--% | -.--% |
Sales 2024 * | 2.22B 1.98B 3.04B | Sales 2025 * | 2.55B 2.28B 3.49B | Capitalization | 13.54B 12.09B 18.55B |
---|---|---|---|---|---|
Net income 2024 * | 431M 385M 590M | Net income 2025 * | 675M 603M 924M | EV / Sales 2024 * | 5.2 x |
Net cash position 2024 * | 2B 1.79B 2.74B | Net cash position 2025 * | 2.81B 2.51B 3.85B | EV / Sales 2025 * | 4.21 x |
P/E ratio 2024 * |
33.2
x | P/E ratio 2025 * |
21.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.2% |
Latest transcript on Neurocrine Biosciences, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Director of Finance/CFO | 44 | 17-10-31 | |
Jude Onyia
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-11-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 99-03-31 |
George Morrow
BRD | Director/Board Member | 72 | 15-09-30 |
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.19% | 121B | |
+19.91% | 114B | |
-19.80% | 20.43B | |
-16.19% | 16.55B | |
-13.45% | 16.45B | |
-44.35% | 15.59B | |
+66.67% | 15.19B | |
+119.39% | 10.96B | |
+19.33% | 8.15B |
- Stock Market
- Equities
- NBIX Stock
- NB3 Stock